ClinicalTrials.gg

Program

zanzalintinib

Also written as “Zanzalintinib” and “XL092”.

Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Adenoma, Islet Cell, led by 3 companies.

Furthest: phase 3, since Jun 16, 202217 company-led studies, 15 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exelixis1312 open or runningphase 3since Jun 16, 2022Feb 15, 2019Dec 15, 2026phase 3 · NCT05678673
Merck33 open or runningphase 3since Nov 7, 2025Jun 25, 2025Nov 27, 2030phase 3 · NCT07489495
Hoffmann-La Roche10 open or runningphase 2since Nov 7, 2017Nov 7, 2017none ahead

Also a collaborator on its studies: Bristol-Myers Squibb and Arcus Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 7, 2017.

  1. Jun 16, 2022Phase 3 study in Colorectal NeoplasmsExelixis · NCT05425940 · 901 enrolled · United States, Australia, Belgium and more
  2. Dec 23, 2022Phase 3 study in Non-Clear Cell Renal Cell CarcinomaExelixis · NCT05678673 · 317 enrolled · United States, Argentina, Australia and more
  3. Oct 9, 2023Phase 3 study in Squamous Cell Carcinoma of Head and NeckExelixis · NCT06082167 · 600 enrolled · United States, Argentina, Australia and more
  4. Dec 19, 2023Phase 1 study in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsExelixis · NCT06191796 · 25 enrolled · United States
  5. Apr 17, 2025Phase 3 study in Adenoma, Islet CellExelixis · NCT06943755 · 440 planned · United States, Australia, Austria and more
  6. Apr 30, 2025Phase 1 study in Hepatic ImpairmentExelixis · NCT06962332 · 20 planned · United States
  7. Jun 25, 2025Merck's first study: phase 2 study in Carcinoma, Renal CellNew to MerckMerck · NCT07049926 · 140 planned · United States, Chile, France and more
  8. Nov 7, 2025Phase 3 study in Carcinoma, Renal CellMerck · NCT07227402 · 904 planned · United States, Argentina, Australia and more
  9. Feb 19, 2026Phase 2 study in MeningiomaExelixis · NCT07428616 · 100 planned · United States
  10. Mar 20, 2026Phase 3 study in Carcinoma, Renal CellMerck · NCT07489495 · 758 planned · United States, Argentina, Australia and more
  11. May 27, 2026Phase 3 study in NeoplasmsExelixis · NCT07620574 · 5,000 planned · United States
  12. Aug 3, 2026Phase 3 study in Colorectal NeoplasmsExelixis · NCT07750158 · 600 planned · United States
  13. Aug 12, 2026Phase 1 study in NeoplasmsExelixis · NCT07773454 · 18 planned
  14. Sep 22, 2026Phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)Exelixis · NCT07845786 · 60 planned · United States

Ahead

  1. Dec 15, 2026Primary completion: phase 3 study in Non-Clear Cell Renal Cell CarcinomaExelixis · NCT05678673
  2. Jan 31, 2027Primary completion: phase 1 study in Carcinoma, Renal CellExelixis · NCT05176483
  3. Feb 29, 2028Primary completion: phase 2 study in MeningiomaExelixis · NCT07428616
  4. Jun 15, 2028Primary completion: phase 2 study in Squamous Non-Small Cell Lung Cancer (NSCLC)Exelixis · NCT07845786

TargetBeta

“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, ”NCIt, by rule

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07845786Squamous Non-Small Cell Lung Cancer (NSCLC) · United States2RecruitingExelixisJun 15, 202860
NCT07773454Neoplasms1Not yet recruitingExelixisJul 31, 202818
NCT07750158Colorectal Neoplasms · United States3RecruitingExelixisApr 5, 2030600
NCT07620574Neoplasms · United States3By invitationExelixisMay 31, 20305,000
NCT07489495Carcinoma, Renal Cell · United States, Argentina, Australia and more3RecruitingMerckNov 27, 2030758
NCT07428616Meningioma · United States2RecruitingExelixisFeb 29, 2028100
NCT07227402Carcinoma, Renal Cell · United States, Argentina, Australia and more3RecruitingMerckFeb 27, 2032904
NCT07049926Carcinoma, Renal Cell · United States, Chile, France and more2RecruitingMerckOct 26, 2031140
NCT06962332Hepatic Impairment · United States1RecruitingExelixisDec 202520
NCT06943755Adenoma, Islet Cell · United States, Australia, Austria and more3RecruitingExelixisJun 30, 2029440
NCT06191796Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors · United States1TerminatedExelixisMay 12, 202525
NCT06082167Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3Active, not recruitingExelixisAug 2028600
NCT05678673Non-Clear Cell Renal Cell Carcinoma · United States, Argentina, Australia and more3Active, not recruitingExelixisDec 15, 2026317
NCT05425940Colorectal Neoplasms · United States, Australia, Belgium and more3Active, not recruitingExelixisJun 16, 2026901
NCT05176483Carcinoma, Renal Cell · United States, Australia, Austria and more1RecruitingExelixisJan 31, 20271,394
NCT03845166Neoplasms · United States, Australia, Belgium and more1Active, not recruitingExelixisAug 31, 2026325
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedHoffmann-La RocheOct 14, 2025314

How it is read

Names in the registry

  • “Zanzalintinib”, 12 entries
  • “XL092”, 4 entries
  • “zanzalintinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.